Bevacizumab With Angiostatin-armed oHSV Increases Antiangiogenesis and Decreases Bevacizumab-induced Invasion in U87 Glioma

Bevacizumab (BEV) is an antiangiogenic drug approved for glioblastoma (GBM) treatment. However, it does not increase survival and is associated with glioma invasion. Angiostatin is an antiangiogenic polypeptide that also inhibits migration of cancer cells, but is difficult to deliver. Oncolytic viru...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhang, Wei, Fulci, Giulia, Buhrman, Jason S, Stemmer-Rachamimov, Anat O, Chen, John W, Wojtkiewicz, Gregory R, Weissleder, Ralph, Rabkin, Samuel D, Martuza, Robert L
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3255598/
https://ncbi.nlm.nih.gov/pubmed/21915104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2011.187
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados